Compounds > lestaurtinib
Page last updated: 2024-09-03

lestaurtinib and gefitinib

lestaurtinib has been researched along with gefitinib in 3 studies

Compound Research Comparison

Studies
(lestaurtinib)		Trials
(lestaurtinib)		Recent Studies (post-2010)
(lestaurtinib)		Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010) (gefitinib)
12412635,2315662,919

Protein Interaction Comparison

ProteinTaxonomylestaurtinib (IC50)gefitinib (IC50)
epidermal growth factor receptor isoform a precursorHomo sapiens (human)0.004
Cyclin-G-associated kinaseHomo sapiens (human)0.42
Multidrug resistance-associated protein 4Homo sapiens (human)4.6
Tyrosine-protein kinase ABL1Homo sapiens (human)1.2
Epidermal growth factor receptorHomo sapiens (human)0.3676
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.5699
Cytochrome P450 1A2Homo sapiens (human)0.151
Cytochrome P450 2E1Homo sapiens (human)0.46
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.7
Tyrosine-protein kinase HCKHomo sapiens (human)0.11
Quinolone resistance protein NorAStaphylococcus aureus9.7
Cytochrome P450 2C8Homo sapiens (human)0.151
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)1.1
Serine/threonine-protein kinase B-rafHomo sapiens (human)2
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)0.008
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.281
Cytochrome P450 2C19Homo sapiens (human)0.151
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)0.0073
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.9742
Ephrin type-B receptor 4Homo sapiens (human)1
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.001
Transcription factor p65Homo sapiens (human)0.055
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.086
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.29

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bharate, SB; Raghuvanshi, R1

Other Studies

3 other study(ies) available for lestaurtinib and gefitinib

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022